Table 3. Comparison of Hematopoietic Stem Cell Products
| | PBSCs | BM | Cord Blood | T-cell Depleted BM/PBSCs | Haploidentical T-cell Depleted BM/PBSCs |
| T-cell content | High | Moderate | Low | Very low | Very low |
| CD34+ content | Moderate–high | Moderate | Low (but higher potency) | Moderate–high | Moderate–high |
| Time to neutrophil recovery | Rapid (13–25 d) | Moderate (15–25 d) | Slow (16–55 d) | Moderate (15–25 d) | Moderate (15–25 d) |
| Early post-HCT risk of infections, EBV-LPD | Low–moderate | Moderate | High | Very High | Very High |
| Risk of graft rejection | Low | Low–moderate | Moderate–high | Moderate–high | Moderate–high |
| Time to immune reconstitutiona | Rapid (6–12 mo) | Moderate (6–18 mo) | Slow (6–24 mo) | Slow (6–24 mo) | Slow (9–24 mo)b |
| Risk of acute GVHD | Moderate | Moderate | Moderate | Low | Low |
| Risk of chronic GVHD | High | Moderate | Low | Low | Low |
| BM = bone marrow; EBV-LPD = Epstein-Barr virus–associated lymphoproliferative disorder; GVHD = graft-versus-host disease; HCT = hematopoietic cell transplantation; PBSCs = peripheral blood stem cells. |
| aAssuming no development of GVHD. If patients develop GVHD, immune reconstitution is delayed until resolution of the GVHD and discontinuation of immune suppression. |
| bIf a haploidentical donor is used, longer times to immune reconstitution may occur. |
